The Hidden Operational Complexity Behind Precision Oncology

Precision oncology is one of those terms that has become part of our everyday vocabulary. It’s a concept that has gained significant attention in various settings, including conference presentations, investor calls, scientific publications, and clinical trial protocols.

The idea behind precision oncology is compelling: instead of treating every patient with the same disease with the same approach, we are increasingly tailoring therapy based on the unique biology of an individual’s tumor. This shift represents one of the most significant advancements in oncology in recent decades.

When people talk about precision oncology, the conversation almost always revolves around the scientific aspects, such as biomarkers, mutations, genomic sequencing, and targeted therapies. These breakthroughs certainly deserve the attention they receive. However, I’ve become convinced that the real challenge isn’t simply discovering precision medicines, but in effectively delivering them.

Behind every biomarker-driven trial is an enormous amount of operational complexity that most people are unaware of. In many cases, this complexity determines whether groundbreaking scientific discoveries ever reach patients.

Precision Medicine Is Anything But Simple

Precision oncology presents an intriguing paradox. While therapies are becoming more precise, the development process is becoming more complicated. 

Years ago, oncology trials typically asked a relatively straightforward question: “Does this therapy improve outcomes in patients with a specific type of cancer?” Today, the question has evolved to a much more nuanced one: “Does this therapy improve outcomes in patients whose tumors carry a specific molecular alteration, identified through a validated test, within a defined treatment setting, while accounting for prior therapies, resistance mechanisms, and evolving standards of care?” 

This shift in focus requires a significantly different approach to study design and execution. Each layer of biological precision introduces additional complexities and challenges in terms of operational execution.

Finding the Right Patient Has Become One of the Hardest Parts

One of the most biggest changes I’ve seen throughout my career is how dramatically patient identification has evolved. In the past, the primary focus was on determining the disease type. Now, in today’s landscape, finding the right patient often begins long before the patient is even screened.

Several important factors come into play in this process: Has comprehensive genomic testing been conducted? Was the correct assay utilized? Is the biomarker result recent enough? Does it meet the protocol requirements? Should central confirmation be performed? Will additional tissue be necessary? Can archived tissue be used?

Every answer significantly influences whether a patient can even be considered for enrollment. While scientific advancements may identify the right patient, the operational process ultimately determines whether that patient actually participates in the study.

Biomarkers Create New Timelines

One thing precision oncology has taught us is that biology doesn’t always align with operational reality. A patient may seem like an ideal candidate, but obtaining tissue, shipping samples, conducting testing, reviewing results, and confirming eligibility are all crucial steps. 

Meanwhile, during this time, the patient’s disease may continue to progress. In oncology, time is of the essence. Delays that seem relatively minor on paper can become clinically meaningful in practice. Therefore, biomarker strategy is not just a scientific discussion; it’s an operational one.

Every Additional Step Creates Another Opportunity for Variability

One lesson I’ve learned is that complexity doesn’t usually emerge all at once. Instead, it accumulates gradually. For instance, a local laboratory may interpret a result differently from a central laboratory, or one site may have extensive experience with genomic testing while another is still developing those capabilities. Even sample handling, turnaround times, and testing platforms can vary. 

While these issues don’t necessarily derail a study, they collectively introduce variability that teams must actively manage. Precision medicine doesn’t eliminate uncertainty; it simply shifts where uncertainty lives.

Protocols Have Become More Demanding

As therapies become more targeted, protocols naturally become more detailed. Eligibility criteria become increasingly stringent, and biomarker requirements expand. Companion diagnostic procedures become more complex, and testing algorithms become more sophisticated.  

From a scientific standpoint, this makes perfect sense. However, operationally, every additional requirement impacts study execution. During protocol reviews, I’ve found myself asking a more important question: not just, “Is this scientifically justified?” but also, “Can investigators realistically execute this consistently across every participating site?”

Medical Monitoring Has Evolved Alongside Precision Oncology

Medical monitoring has undergone significant changes since I started my career. Eligibility discussions have expanded beyond laboratory values and performance status, now encompassing molecular pathology reports, biomarker eligibility, genomic findings interpretation, and addressing discrepancies between local and central testing.  

Investigators are also increasingly navigating sophisticated inclusion criteria. Many of these conversations focus on biology, operational execution, and clinical judgment, rather than safety alone. The role continues to evolve as oncology itself evolves.

The Future Depends on Better Integration

One thing precision oncology has taught our industry is that success depends on far more than discovering an effective therapy. It requires diagnostics that work, efficient laboratory communication, investigators who can interpret results with confidence, timely information for medical monitors, and processes that support increasingly specialized studies. 

Manufacturing, logistics, regulatory strategy, and data management all become an integral part of the same conversation. The days of treating these functions independently are disappearing, as precision oncology demands integration.

The Patient Experience Must Stay at the Center

Sometimes, in discussions about biomarkers and genomic sequencing, it’s easy to become fixated on technology. However, I think it’s important to remember what patients experience. This includes additional biopsies, longer waiting periods, more appointments, additional testing, and increased uncertainty. 

As our studies become more sophisticated, we also have a responsibility to ensure that participation is as practical as possible. Scientific complexity should never translate into unnecessary burdens for patients. The most successful development programs never lose sight of this balance.

Operational Excellence Is Becoming a Scientific Advantage

Over the past few years, I’ve come to realize that operational execution is no longer simply supporting precision oncology; it’s actually enabling it.

You can have the right biomarker, the right target, and the right therapy. However, if patients can’t be identified efficiently, if tissue can’t be processed reliably, if testing creates prolonged delays, or if investigators struggle to interpret eligibility, the science never has the chance to demonstrate its value.

That’s why I view operational excellence as an integral part of the scientific strategy itself, not something that happens afterward.

A Final Thought

Precision oncology has fundamentally changed the way we think about cancer. Instead of solely focusing on the tumor’s origin, we’re now asking what drives it. This is one of the greatest scientific advances of our generation. However, every advancement creates new responsibilities. As therapies become more personalized, their development becomes more interconnected with various domains: biology, diagnostics, operations, medical monitoring, and clinical execution. Each of these elements becomes essential to the overall success of the entire process. 

I firmly believe that the organizations leading the next era of oncology won’t simply be those with the most innovative science. Instead, they’ll be the ones that recognize something our industry is only beginning to fully appreciate. 

Precision medicine doesn’t reduce complexity; it redistributes it. And the companies that learn to manage this hidden operational complexity will be the ones who consistently translate extraordinary science into extraordinary outcomes for patients.